Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Monoclonal antibodies have revolutionized cancer therapy. However, delivery to tumor cells in vivo is hampered by the large size (150 kDa) of conventional antibodies. The minimal target recognition module of a conventional antibody is composed of two non-covalently associated variable domains (VH an...
Salvato in:
| Autori principali: | , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2017-11-01
|
| Serie: | Frontiers in Immunology |
| Soggetti: | |
| Accesso online: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.01603/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|